Protagonist Therapeutics, Inc
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $46.0 | $434.4 | $60.0 | $26.6 | $27.4 |
| Operating income | -$158.1 | $252.8 | -$93.7 | -$131.4 | -$125.8 |
| Net income | -$130.1 | $275.2 | -$79.0 | -$127.4 | -$125.6 |
| Cash Flow Statement | |||||
| Free cash flow | $56.1 | $182.8 | -$70.8 | -$108.9 | -$109.0 |
Shares outstanding 64.7M · Free float 94.6%
Annual filing data through FY ended December 31, 2025; float as of September 28, 2026.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground